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Abstract Transaldolase is a key enzyme of the pentose phos- 
phate pathway. While antibody (Ab) 169, directed against the 
N-terminal 139 residues of human transaldolase (TAL-H), had 
no effect on enzyme activity, Ab 12484 raised against full length 
and functional recombinant TAL-H inhibited catalytic activity. 
This tentatively mapped the catalytic site to the C-terminal 140- 
336 amino acid portion of TAL-H. Dihydroxyacetone transfer 
reactions catalyzed by transaldolase depend on Schiff base for- 
mation by a iysine residue. Replacement of lysine-142 by glutam- 
ine using site-directed mutagenesis resulted in a complete loss of 
enzyme activity, suggesting that lysine-142 is essential for the 
catalytic activity of TAL-H. 
Key" words'." Transaldolase; Antibody-mediated inhibition; 
Site-directed mutagenesis 
1. Introduction 
The pentose phosphate pathway (PPP) enzyme transaldolase 
catalyzes the transfer of a C3 fragment corresponding to dihy- 
droxyacetone from sedoheptulose 7-phosphate to glyceralde- 
hyde 3-phosphate forming erythrose 4-phosphate and fructose 
6-phosphate. PPP fulfills two essential functions, formation of 
ribose 5-phosphate for synthesis of nucleotides and generation 
of NADPH for biosynthetic reactions and to maintain glutathi- 
one at a reduced state, thus, to protect sulfhydryl groups and 
cellular integrity from oxygen radicals [1]. Importance of PPP 
has been documented in host defense mechanisms in all tissues 
against oxidative stress [1], in embryogenesis [2], neurulation 
[3], myelination [4], inflammation [5-8], lymphocyte activation 
[9,10], phagocytosis [6,8], cardiac arrhythmias [11], resistance 
to radiation of malignant umors [12]. We recently demon- 
strated that transaldolase is expressed selectively in oligoden- 
drocytes at high levels, possibly linked to production of large 
amounts of lipids as a major component of myelin and to the 
protection of myelin sheaths from oxygen radicals and that 
high-affinity autoantibodies to human transaldolase (TAL-H) 
are present in serum and cerebrospinal fluid of patients with 
multiple sclerosis (MS) [13]. 
The active site of transaldolase of Candida utilis includes 
seven amino acids around a lysine residue that mediates Schiff 
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base formation during the dihydroxyacetone-transfer reaction 
[14,15]. In the yeast Saccharomyces cerevisiae replacement of 
a single lysine residue at position 144 of yeast transaldolase 
(TAL-Y) resulted in a complete loss of enzyme activity [16]. 
Other residues in the active site did not appear essential for 
function of TAL-Y [16]. In the present study, we demonstrate 
that antibody 169, raised against a 139 amino acid long N- 
terminal domain of TAL-H [17], had no effect on enzyme activ- 
ity, while Ab 12484, raised against a full length and functional 
recombinant TAL-H molecule, suppressed enzyme activity. In- 
hibition by Ab 12484 was reduced in the presence of excess 
substrate concentrations, uggesting that an interaction with 
the catalytic site of TAL-H may be responsible, at least in part, 
for antibody-mediated inhibition of enzyme activity. Using 
amino acid replacement by site-directed mutagenesis, we show 
that lysine-142 is critical for catalytic activity of human transal- 
dolase (TAL-H). 
2. Materials and methods 
2.1. Prokaryotic expression ofrecombinant protein 
Full-length TAL-H protein was expressed as a fusion protein with 
glutathione S-transferase (GST) encoded by pGEX-2T plasmid vector 
[18]. A BgIII site was generated by polymerase chain reaction mediated 
mutagenesis immediately 5' of the first methionine codon of TAL-H 
cDNA [17]. The open reading frame of TAL-H was amplified by PCR 
using a set of 5' (4/2BgIII, 5'-GTA-CTT-AGA-TCT-ATG-TCG-AGC- 
TCA-CCC-GTG-3'; first methionine codon of TAL-H is underlined) 
and 3' (oligodT-18) primers and cloned directly into the pCR-1000 
vector (InVitrogen, San Diego, CA). Subsequently, a 1033 nucleotide 
long BglII fragment of cDNA clone 412-4/1, between ucleotide posi- 
tions 57 and 1090, respectively, was transferred into the BamHI site of 
pGEX-2T, immediately downstream of the thrombin cleavage site. 
Optimum stimulation of expression of the recombinant fusion protein 
was obtained with 1 mM isopropylthio-fl-galactoside (IPTG) after 2 h. 
TAL-H/GST fusion protein was affinity-purified through binding of 
GST to glutathione-coated agarose beads as specified by the supplier 
(Pharmacia). TAL-H protein was cleaved from GST by 1 NIH unit of 
thrombin (Sigma, St. Louis, MO) in 1 ml of PBS containing 600 ,ug 
fusion protein. TAL-H protein was separated from the agarose bead- 
bound GST by centrifugation. 
2.2. Antibodies 
Highly specific polyclonal antibodies 169 and 170 directed to the 139 
amino acid long N-terminal segment of TAL-H were developed earlier 
[17]. Antibody 12484 to the functional 336 amino acid long full length 
recombinant TAL-H was raised in rabbits as earlier described [17]. For 
enzyme inhibition assays, immunoglobulins were precipitated from sera 
with 50% ammonium sulfate [19], dialyzed against phosphate buffered 
saline pH 7.4, and quantified by the Bradford assay [20]. 
2.3. Testing of transaldolase enzyme activity 
Transaldolase enzyme activity was measured by the transfer of the 
dihydroxyacetone three-carbon u it from the donor D-fructose-6-phos- 
phate, to the acceptor D-erythrose-4-phosphate [21]. Enzyme activity 
was assayed in the presence of 3.2 mM D-fructose 6-phosphate, 0.2 mM 
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D-erythrose-4-phosphate, 0.1 mM NADH, 10 /~g of ~-glycero- 
phosphate dehydrogenase/triosephosphate isom rase at a 1 : 6 ratio in 
40 mM triethanolamine, 10mM EDTA pH 7.6 at room temperature 
by continuous absorbance r ading at 340 nm for 10 min. The assay was 
conducted in the activity range of 0.0014).01 units/ml using yeast ran- 
saldolase (TAL-Y, Sigma, St. Louis, MO) and, subsequently, rTAL-H 
as positive controls. For antibody-mediated inhibition assays, 50 ng of 
rTAL-H in PBS was pretreated with purified immunoglobulins for 30 
rain at 4°C and tested for enzyme activity. 
2.4. Site-directed mutagenesis 
A single mutagenic oligonucleotide, in addition to two outer amplfli- 
cation primers, in a single amplification/mutagenesis r action was util- 
ized. Prior to amplification, the mutagenic oligonucleotide was 
phosphorylated with T4 polynucleotide kinase (GIBCO-BRL) and, 
subsequently, incorporated into the amplification product by including 
a thermostable ligase during PCR [22]. Thus, mutagenic PCR reaction 
was performed by including a phosphorylated mutagenic oligonucleo- 
tide (4/lm, corresponding to positions 467498 of TAL-H cDNA, 5'- 
CCG-AAT-TCT-TAT-ACA-GCT-GTC-ATC-AAC-CTG-GG-Y to 
achieve an A~C mutat~n at the underlined nucleotide position 480) 
with the previously utilized two outer 5' (412BglII) and 3' (oligodT-18) 
amplification primers. PCR reactions included 200 pmol of each of the 
three primers, 200 HM of each dNTP, thermostable igase buffer (25 
mM potassium acetate, 20 mM Tris pH 7.6, 10 mM magnesium acetate, 
0.1% Triton X-100, 10 mM dithiothreitol, 1 mM NAD+), 5 U of 7~lq 
DNA polymerase (Perkin-Elmer/Cetus), 40 U of Taq ligase (New Eng- 
land Biolabs,), and 1/lg of p4/2-4/1 template DNA [17]. The amplified 
products were cloned into the pCRII vector (Invitrogen, San Diego, 
CA). Resultant plasmids were sequenced by the chain termination 
method [23] and analyzed for the presence of the planned point muta- 
tion (at position 480 for mutagenic oligonucleotide 4/lm) and absence 
of unwanted mutations. Clone 4/lm 2 with the desired mutation was 
digested with BgIII restriction enzyme, utilizing recognition sites in the 
5' outer primer and downstream of the polyadenylation signal, and 
cloned into the BamHI site of the pGEX-2T vector [18]. The mutated 
TAL-H (mTAL-H) was expressed as a fusion protein with GST as 
described for wild-type human transaldolase (rTAL-H). 
2.5. Western blot analysis 
500 ng of recombinant TAL-H protein in 10 pl per well was separated 
by SDS-PAGE and electroblotted to nitrocellulose [24]. Nitrocellulose 
strips were incubated in 100 mM Tris pH 7,5, 0.9% NaCI, 0.1% Tween 
20, and 5% skim milk, with antibodies (at a 1000-fold dilution unless 
indicated otherwise) for 1 h at room temperature. For detection of 
rabbit antibodies, after washing, the strips were incubated with horse- 
radish peroxidase-conjugated goat anti-rabbit IgG (Boehringer 
Mannheim, Indianapolis, IN). In between the incubations the strips 
were vigorously washed in 0.1% Tween-20, 100 mM Tris pH 7.5, and 
0.9% NaCI. The blots were developed with a substrate comprised of 
1 mg/ml 4-chloronaphthol and 0.003% hydrogen peroxide. 
2.6. ELISA 
96-well plates were precoated at 4°C with 100 ng of antigen per well 
in 0.01 M NaHCO 3 (pH 9.55). Uncoated sites were blocked with 10% 
goat serum/0.1% Tween-20 in PBS pH 7.4 at room temperature for 1 h. 
Subsequently, sera were added to the wells in 10% goat serum/0, l% 
Tween-20 in PBS. After incubation for 1 h, the plates were washed with 
0.1% Tween-20 in PBS. The plates were then further incubated with 
horseradish peroxidase-conjugated secondary antibodies, washed with 
0.1% Tween-20 in PBS, and developed with 2,2'-azino-bis(2-eth- 
ylbenzthiazoline-6-sulfonic ac d) as earlier described [25]. 
3. Results and discussion 
3.1. Production of  fully functional human recombinant 
transaldolase (r TAL-H) 
The full-length TAL-H protein was expressed as a fusion 
protein with glutathione S-transferase (GST) encoded by 
pGEX-2T plasmid vector. By Western blot analysis of protein 
lysates, a 66 kDa fusion protein (38 kDa TAL-H+28 kDa GST) 
was detected using antibody 169 [17]. TAL-H/GST fusion pro- 
A 
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Fig. 1. Expression and affinity-purification f full-length TAL-H pro- 
tein. (A) SDS-PAGE of protein lysates. A 66 kDa fusion protein con- 
taining the 38 kDa TAL-H protein fused to the 28 kDa GST protein 
was expressed in the pGEX-2T/TAL-H/Sense construct. (B) SDS- 
PAGE analysis of products after successive steps of purification. The 
66 kDa fusion protein was affinity-purified from the total bacterial 
lysate through binding to glutathion-coated agarose beads (lane GST/ 
TAL-H). The fusion protein was cleaved with thrombin to separate 
TAL-H from GST. Lane 'GST/TAL-H + thrombin' shows result of 
proteolytic leavage. TAL-H protein was separated from the agarose 
bead-bound GST by centrifugation (lane TAL-H). 
tein was affinity-purified through binding of GST to glu- 
tathion-coated agarose beads, cleaved from GST with throm- 
bin, and the TAL-H protein was separated from the agarose 
bead-bound GST by centrifugation (Fig. 1). The purified full 
length recombinant TAL-H (rTAL-H) was found to be highly 
functional in the transaldolase nzyme assay by showing a 
specific activity of -> 15 U/mg protein. As references, purified 
yeast transaldolase (TAL-Y) had an enzyme activity o f -12  
U/rag protein, while normal human lymphocytes contain 0.015 
U transaldolase activity/mg of total protein [17]. 
3.2. Inhibition of enzymatic aetivity by Ab 12484 raised against 
the full length TAL-H protein lack of inhibition by Ab 169 
directed against residues 1 139 of TAL-H 
TAL-H-specific rabbit Ab 169 directed to the N-terminal 139 
amino acid long segment of TAL-H [17] and Ab 12484, raised 
against the full length TAL-H protein, were utilized to map 
functionally relevant domains of TAL-H. Abs 169 and 12484 
displayed similar levels of binding affinity to rTAL-H based on 
a quantitative ELISA assay (Fig. 2A). Pretreatment o f rTAL-H 
with Ab 169 up to a concentration of 1 mg/ml had no effect on 
enzymatic activity of rTAL-H (Fig. 2B). By contrast, Ab 12484 
dose-dependently suppressed enzymatic activity of rTAL-H. 
Maximal suppression by Ab 12484 was obtained at a concen- 
tration of 300 gg/ml. To ensure that the inhibitory effects were 
due to the presence of antibodies and not other factors, immu- 
noglobulins precipitated from inhibitory sera with 50% ammo- 
nium sulfate, were utilized. Preimmune rabbit sera had no effect 
on enzyme activity under similar conditions. 
3.3. Enzyme-inhibitory activity of Ab 12484 is partially 
reversible by substrate xcess 
TAL-H activity was routinely measured using fructose 6- 
phosphate as the dihydroxyacetone donor substrate. Assays 
were done in the presence of 3.2 mM fructose 6-phosphate 
which allowed determinations of enzymatic activity at maximal 
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velocity (Fig. 3). Under these conditions activity of TAL-H was 
suppressed in the presence of Ab 12484 by as much as 74%. To 
determine whether antibody-mediated suppression of enzy- 
matic activity involved an interaction with the catalytic site of 
TAL-H, concentration of fructose 6-phosphate was increased 
during the enzyme assay. The inhibitory effect of Ab 12484 on 
transaldolase activity could be partially overcome by addition 
of excess of  fructose 6-phosphate (Fig. 3). Increasing the con- 
centration of fructose 6-phosphate from 3.2 mM to 320 mM 
augmented activity of Ab 12484-treated TAL-H from 1.9 + 0.1 
to 4.9 + 0.4 U/mg enzyme protein. These findings indicate that 
Ab 12484 decreases both affinity of the enzyme for fructose 
6-phosphate and the Vm, x (Kcat) of the reaction. Based on a lack 
of inhibition by Ab 169, the catalytic site of TAL-H was tenta- 
tively allocated to the C-terminal portion (residues 140-336) of 
the molecule. 
3.4. Lysine 142 mediates catalytic activity of  TAL -H  
The active site of  TAL in C. utilis has been mapped to a 
heptapeptide around a lysine residue which directly mediates 
Schiff base formation in the dihydroxyacetone transfer eaction 
22 
2 
1.8 
1.6 
1.4 
08 
06  
O4 
02  
0 
5 
T 
pre 169 Ab 169 pre 12484 Ab 12484 
18 
16 
14 
.¢ 12 
P lO =L 
~8 
5 
6 
4 
2 
0 
Ab169 pre 12484 Ab12484 mTAL-H 
Fig. 2. (A) Binding of preimmune rabbit sera (pre) and TAL-H specific 
Abs 169 and 12484 to 100 ng of affinity-purified human recombinant 
transaldolase (rTAL-H) in ELISA. Antibodies were added at a dilution 
of 1 : 1,000. Values indicate mean + S.D. of four parallel optical density 
measurements at 405 nm. (B) Inhibition of enzymatic activity of rTAL- 
H by Ab 12484. 50 ng of rTAL-H was preincubated with 300 pg of 
purified immunoglobulins from the indicated sera for 30 min at 4°C in 
500 pl of PBS pH 7.4 and assayed for enzyme activity. Values indicate 
mean + S.D. of four independent measurements. Enzyme activity of 
mutant TAL-H with Lys --~ Gln substitution at position 142 (mTAL- 
H) was < 1% of that of wild-type rTAL-H. *significant suppression: 
P < 0.0h 
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Fig. 3. Effect of excess fructose 6-phosphate substrate on inhibition of 
transaldolase activity by Ab 12484. Following preincubation without 
(Control) or with 300/~g of Ab 12484 for 30 rain (Ab 12484), enzymatic 
activity of 50 ng of rTAL-H was measured in the presence of fructose 
6-phosphate atthe indicated concentrations. Values represent mean of 
three experiments. 
[14,26]. Sequence alignment of active site heptapeptides of TAL 
from C. utilis [14] and S. cerevisiae [16] with a corresponding 
heptapeptide of TAL-H [17] revealed that in addition to the 
essential lysine residues mediating Schiff base formation with 
the substrate, the remaining residues are identical or function- 
ally homologous except for substitution of an alanine in both 
TAL-C and TAL-Y with a serine at position 144 in TAL-H 
(Fig. 4). Both TAL-Y and TAL-H are rich in lysines. While 
TAL-H contains 31 lysines, TAL-Y has 36 lysine residues. The 
overall homology between TAL-H and TAL-Y is 58% [17]. 
Lysine-144 in TAL-Y is critical for its activity [16] and it corre- 
sponds to lysine-142 in TAL-H. To determine the significance 
of lysine-142 in the catalytic activity of TAL-H, it was replaced 
by glutamine creating an A--*C mutation at nucleotide position 
480 in the TAL-H eDNA clone 412-4ll [17]. Absence of un- 
wanted mutations was verified by sequencing the expression 
vector carrying the mutant cDNA 4/ lm 2 (Fig. 5A). The mutant 
TAL-H protein (toTAL-H) was expressed in E. coli JM101 
bacteria as a 66 kDa fusion protein with the 28 kDa GST 
protein as described for wild-type TAL-H. The fusion protein 
was affinity-purified from the total bacterial lysate through 
TAL-C I_KIASTY 
IIIIII: 
TAL-Y IKIASTW 
II :xlll 
TAL-H I_KLSSTW 
Fig. 4. (A) Sequence homologies between the translated amino acid 
sequence of eDNA 4/2-4/1 (TAL-H) and the yeast transaldolase pro- 
tein (TAL-Y). Potential phosphorylation sites are indicated in TAL-H. 
Calmodulin-dependent protein kinase (Calkin) and cAMP-dependent 
protein kinase (cAMP-P) sites are underlined with solid lines. Casein 
kinase I] recognition motifs are in italic and underlined. Serine and 
threonine residues in potential protein kinase C phosphorylation sites 
are marked with asterisks. A lysine (K) residue at position 144 that has 
been shown to be essential for function of TAL-Y, corresponding to
position 142 in TAL-H, is bold-faced and underlined. (B) Sequence 
alignment of the active sites in TAL from C. utilis (TAL-C), S. cerevis- 
iae (TAL-Y), and man (TAL-H). Lysine residues (K) potentially in- 
volved in Schiff base formation with the substrate are underlined. Iden- 
tical (J), functionally homologous (:), and functionally dissimilar (x: A, 
neutral/hydrophobic versus S, neutral/polar) esidues are indicated. 
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Fig. 5. Site-directed mutagenesis of TAL-H. (A) Nucleotide sequence 
of wild-type TAL-H cDNA clone 4/2-4/1 and of mutant clone 4/lm~. 
Lysine-142 of TAL-H (AAG triplet) was replaced by glutamine (CAG 
triplet) by creating an A ~ C mutation at nucleotide position 480 of 
TAL-H cDNA clone 4/2 4/1. (B) SDS-PAGE and Western blot analy- 
sis of mutant TAL-H protein (mTAL-H). mTAL was expressed and 
affinity-purified as described for wild-type TAL-H. Lanes for SDS- 
PAGE contained 40/.zg of total lysate or 500 ng of purified protein. 
Lanes for Western blot contained 100 ng of purified protein which was 
detected by Ab 169 at a dilution of 1:5,000. 
binding to glutathione-coated agarose beads and mTAL-H was 
cleaved from GST with thrombin. Subsequently, mTAL-H was 
separated from the agarose bead-bound GST by centrifugation. 
Authenticity of mTAL-H was verified based on its molecular 
weight and immunoreactivity with TAL-H specific Ab 169 (Fig. 
5B). Replacement of the lysine residue at position 142 in TAL- 
H resulted in a complete loss ( > 99% suppression) of enzyme 
activity (Fig. 2B). No difference was noted between the wild- 
type or mutant TAL-H in reactivity with Ab 12484, suggesting 
that multiple epitopes outside the catalytic domain of the mol- 
ecule are recognized by these antibodies. 
High-affinity antibodies to TAL-H are present in patients 
with MS [13]. Catalytic activity of wild-type rTAL-H (50 ng) 
was also inhibited in the presence of 300/lg/ml purified immu- 
noglobulins from MS patients ALV and LAK, by 37% and 
26%, respectively (not shown). These data demonstrated that 
autoantibodies from patients with MS recognized not only the 
immunoblotted full-length TAL-H protein and its N-terminal 
fragment [13] but functionally relevant C-terminal epitopes as 
well. The pathological significance of inhibition of transal- 
dolase activity by autoantibodies is unknown at this time, but 
capture of TAL-H by immunoglobulins on the surface of B 
lymphocytes may play an important role in presenting TAL-H 
to T cells. In fact, activated B cells, by virtue of antigen capture 
on their surface immunoglobulins, are particularly efficient pre- 
senters of low abundance antigens [27]. Proliferation of T cells 
was stimulated by TAL-H in both patients (LAK, stimulation 
index, SI = 3.1 [13]; ALV, SI = 4.6, not shown). The identifica- 
tion of enzyme inhibitory autoantibodies capable of binding to 
native TAL-H may provide an example of how specific au- 
toantibodies can influence autoimmune T cell responses in pa- 
tients with MS. 
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